Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence

Table 1 Comorbidities and concomitant medications during 1-30 days and 91-120 days prior to new AMI hospitalization

N = 8,354	Case period 1-30 days before index day	Control period 91-120 days before index day
Comorbidity (%)
Hypertension	41.81	36.65
Diabetes mellitus	23.23	21.58
Osteoarthritis	8.55	7.79
Peptic ulcer disease	7.94	7.17
Chronic lung disease	6.48	6.12
Congestive heart failure	4.30	3.51
Chronic renal disease	3.17	2.82
Chronic liver disease	3.10	2.98
Atrial fibrillation	2.21	1.86
Rheumatoid arthritis	0.81	0.72
Migraine	0.65	0.41
Cancer	0.16	0.16
Concomitant medication (%)
calcium channel blocker	27.16	24.34
ACE inhibitors or ARBs	23.93	20.68
beta-blocker	22.06	17.05
sulfonylurea	15.75	14.97
statins	11.31	10.16
low dose aspirin	7.23	7.88
antihypertensive agents	5.12	4.31
insulin	4.39	3.58
thiazolidinediones	2.54	2.56
glinides	1.83	1.62
loop diuretics	1.59	1.28
non-aspirin antiplatelet agents	1.11	1.21
vitamin k antagonist	0.81	0.67

ISSN: 1471-2261